van de Laar Floris Alexander
Radboud University Nijmegen Medical Centre, Department of General Practice, Nijmegen, The Netherlands.
Vasc Health Risk Manag. 2008;4(6):1189-95. doi: 10.2147/vhrm.s3119.
Alpha-glucosidase inhibitors (AGIs) are drugs that inhibit the absorption of carbohydrates from the gut and may be used in the treatment of patients with type 2 diabetes or impaired glucose tolerance. There is currently no evidence that AGIs are beneficial to prevent or delay mortality or micro- or macrovascular complications in type 2 diabetes. Its beneficial effects on glycated hemoglobin are comparable to metformin or thiazolidinediones, and probably slightly inferior to sulphonylurea. In view of the total body of evidence metformin seems to be superior to AGIs. More long-term studies are needed to study the effects of AGIs compared to other drugs. For patient with impaired glucose tolerance AGIs may prevent, delay or mask the occurrence of type 2 diabetes. A possible beneficial effect on cardiovascular events should be confirmed in new studies.
α-葡萄糖苷酶抑制剂（AGIs）是一类抑制碳水化合物在肠道吸收的药物，可用于治疗2型糖尿病患者或糖耐量受损患者。目前尚无证据表明AGIs对预防或延缓2型糖尿病患者的死亡率或微血管或大血管并发症有益。其对糖化血红蛋白的有益作用与二甲双胍或噻唑烷二酮类药物相当，可能略逊于磺脲类药物。鉴于现有证据，二甲双胍似乎优于AGIs。与其他药物相比，需要更多的长期研究来研究AGIs的效果。对于糖耐量受损的患者，AGIs可能预防、延缓或掩盖2型糖尿病的发生。其对心血管事件可能存在的有益作用应在新的研究中得到证实。
